Generic Firms Sanguine About New Congress, Preparing For Biogeneric Action
Executive Summary
Among a number of potential congressional actions that could benefit the generic industry, generic manufacturers appear to be most bullish about the prospects for the establishment of a pathway for follow-on biologics
You may also be interested in...
Mylan Closes Merck KGaA Merger, Looks To Fill Remaining Pipeline Gaps
Following the close of its acquisition of Merck KGaA's generics unit, Mylan is looking to round out its product portfolio with oncology and women's healthcare products
Mylan Closes Merck KGaA Merger, Looks To Fill Remaining Pipeline Gaps
Following the close of its acquisition of Merck KGaA's generics unit, Mylan is looking to round out its product portfolio with oncology and women's healthcare products
Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver
The success of generic companies will be determined more by the breadth and quality of their offerings than product pricing, Lehman Brothers Senior VP-Specialty Pharmaceutical Research Rich Silver told the Generic Pharmaceutical Association